Life Sciences Archive » December, 2013

Life Sciences - December, 2013

220 articles

• Genzyme Puts Up $22M To Settle FCA Claims
• FDA Permits Last-Resort Iclusig Use After Clinical Trial Deaths
• The Gift That Keeps On Giving (To Defendants)
• US Recouped $3.8B From False Claims Settlements In 2013
• Pfizer Absolved In Quigley Asbestos Injury Suit
• CreAgri's Supplement Patent Invalidated For Lack Of Data
• SAC Manager Martoma's Request To Delay Trial Denied
• Deal Makers Close 2013 With String Of Big Pharma Plays
• Cephalon Sues Hetero Over Generic Leukemia Drug
• Deals Rumor Mill: Hard Rock, Evonik, Vivendi
• Merck Recalls Gardasil Over Glass Particles In Vials
• FDA Extends Comment Period On Generic Drugs Rule
• Female Powerbrokers Q&A: McCarter & English's Pam Moore
• Female Powerbrokers Q&A: Vorys Sater's Benita Kahn
• A Busy Year For Patent Eligibility: 6 Key Decisions
• Generic Fosamax Users Must Give More Details In MDL
• MicroMed Investors Say Execs Lied About Heart Pump Patents
• GNC Glucosamine False Ad Suits Combined In Md.
• Calif. High Court Says Prescription Fee Disclosure Law OK
• Landmark Chemicals Case May Embolden EPA
• Boehringer May Face More Sanctions In Pradaxa MDL
• Big Pharma At Crossroads After GSK Payment Reforms
• JPML Centralizes Glucosamine False Ad Suits
• Bayer Offers $2.9B For Cancer Drugmaker Algeta
• How They Won It: Greenberg Wins Stiefel Securities Verdict
• Unions Worry Over EU-US Trade Deal's Impact On Drug Costs
• AstraZeneca Puts Up $4.1B To Take Over Diabetes Drug JV
• Fed. Circ. Affirms Hanmi Win In Generic Nexium Patent Suit
• $4.75M Ferring, Aventis Antitrust Settlement Earns Approval
• Warner Chilcott Sues Torrent To Block Generic Enablex
• Female Powerbrokers Q&A: Novak Druce's Pat Rogowski
• Female Powerbrokers Q&A: White And Williams' Joan Rosoff
• Merck Unit Hit With €15.3M Competition Fine In France
• Blackstone Passes Indian Drugmaker Stake To Bain
• Post-Actavis, Pay-For-Delay Debate Is Far From Over
• Pain-Pump Seller DJO Lied To Get $10M Policy, Insurer Says
• Teva Hit With Securities Class Action Over CEO Resignation
• Stryker Inks 1st Settlements In NJ Hip Implant Suits
• J&J Fights Attys' Pursuit Of Confidential Risperdal Docs
• Allergan Hit With FCA Kickback Suit Over Eye Drugs
• Radient Pays $2.5M To End Claims It Lied About Mayo Clinic
• MLB Can Depose A-Rod's Cousin, Fla. Appeals Court Says
• Pfizer GC To Step Down Ahead Of Reshuffling
• 3rd Circ. Doubts Jurisdiction In Generic-Fosamax Appeal
• FDA, EMA To Share Generic Drug Inspection Duties
• Female Powerbrokers Q&A: Ober Kaler's Barbara Werther
• Female Powerbrokers Q&A: Dechert's Cathy Botticelli
• A Year Of Change For Life Sciences IP
• SAC Manager Can't Escape Charges Involving Foreign Stocks
• Pfizer Pay-For-Delay Claims Get 2nd Chance
• Life Sciences MVP: Fish & Richardson's Jonathan Singer
• Shook Hardy Reels In Litigation Pro For Orange County Office
• Diet Pill Maker, Snooki Face Suit Over Weight Loss Ads
• Eli Lilly Defeats Soldier's Cymbalta 'Brain Zap' Suit
• GSK To End Doctor Payments To Market Meds
• Female Powerbrokers Q&A: Locke Lord's Denise Hanna
• Female Powerbrokers Q&A: Morrison & Foerster's Anna White
• Spain's Almirall Pledges $400M For Skin Drug Co. Aqua
• 4th Circ. Questions Basis For Generic-Drug Injury Appeal
• Stryker Hip Implant Suit Stays In Federal MDL
• Pa. High Court Jettisons Wyeth's $9M Prempro Appeal
• Chinese Co. To Pay $2.2M To End Vitamin C Antitrust Case
• Life Sciences MVP: Kirkland's Jay Lefkowitz
• VC Firm Can't Collect $7.5M From Transvaginal Mesh Suits
• Lawmakers Float Bill To Ease New Antibiotic Approvals
• Teva Wins Ban On Mylan Parkinson's Generic
• Gov't Sees Outlier Among Off-Label Cases Under FCA
• Top 13 Product Liability Law Developments For 2013
• GSK Seeks To Up Stake In Indian Unit By $1B
• Cogent Ducks Fraud Suit Over Joint Pain Supplement
• Valeant Puts Up $250M For Struggling Solta Medical
• Female Powerbrokers Q&A: Arnold & Porter's Maureen Jeffreys
• Female Powerbrokers Q&A: Fish's Ann Cathcart Chaplin
• High Court Turns Down Teva Unit's Provigil Patent Appeal
• Fen-Phen Malpractice Awards Denied By Texas High Court
• 3rd Circ. Asked To Tackle Venue Dispute In Paxil Suit
• Life Sciences MVP: Morrison & Foerster's David Doyle
• Bankrupt Savient Gets OK For $120M Sale To Crealta
• Torrent Pharma To Pay $323M For Elder's Formulations Biz
• Biosimilars Can't Circumvent BPCIA With Litigation
• FDA Encouraged Illegal Compounding, K-V Tells DC Circ.
• Female Powerbrokers Q&A: Paul Hastings' Elizabeth Noe
• Female Powerbrokers Q&A: Bartlit's Rebecca Weinstein Bacon
• 5 Steps To A Successful Cross-Examination
• Irish High Court Approves Perrigo's $8.6B Elan Buy
• FDA Pushes Medical Device Self-Audit Pilot Program
• Life Sciences MVP: White & Case's Dimitrios Drivas
• 'All Natural' Food Claims: Back To Ad Law Basics
• Novartis Settles Patent Suit Over Organ Transplant Drug
• Chinese Scientists Attempted To Steal Seeds, DOJ Says
• Drugmakers Lose Bid For 'Indefinite' Extension In FTC Case
• AGs Urge FDA To Rethink High-Powered Painkiller Approval
• 4th Circ. Revives Purdue Pharma OxyContin FCA Row
• Female Powerbrokers Q&A: White And Williams' Patti Santelle
• Female Powerbrokers Q&A: Mayer Brown's Debora De Hoyos
• Roche, Prothena Form $600M Parkinson's Partnership
• Bankrupt Savient Takes $120M Bid From Pharma Co. Crealta
• Pharma Co. Investors Can Serve China Execs Via US Counsel
• Life Sciences MVP: Sullivan & Cromwell's Frank Aquila
• P&G Can't Bar Testimony In Fixodent Suit, 11th Circ. Hears
• FDA Pushes To Curb Antibiotic Use In Livestock
• FTC OKs Settlement With Actavis Over Warner Chilcott Buy
• Nexium Direct Purchasers Win Class Cert. In Antitrust MDL
• Weary Judges Urge Tort Attys To Rethink Longshot Motions
• Criticisms Mount On Drug IP Proposals In Pacific Trade Pact
• Fed. Circ. Won't Revive St. Jude Vascular Closure Patent
• How Iran Nuclear Deal May Impact US Medicine Exports
• Fed. Circ. Finds Galderma Acne Gel Patents Obvious In IP Row
• Stryker Fax Recipients Win Class Cert. In TCPA Suit
• Risperdal Plaintiffs Push For Release Of J&J Studies
• Female Powerbrokers Q&A: Morrison Cohen's Danielle Lesser
• Female Powerbrokers Q&A: Liner Grode's Angela Agrusa
• The Rise Of Predictive Coding For Life Sciences
• Invitae Wants Myriad's Gene-Testing Patent Suit Tossed
• Plaintiffs' Firm Wants Ex-Associate's Fee Claim Arbitrated
• Firm Says Novartis Whistleblower Owes Fees For Failed Suit
• FTC Tries Pulling Teva Into Cephalon Pay-For-Delay Suit
• NJ Hospital Gets Criminal Docs On Bristol-Myers Black Widow
• Align Technology, Execs Dodge Proposed Fraud Class Action
• Ex-Hansen Medical VP Can't Shake SEC's Fraud Claims
• CVS Caremark, Cardinal Health Form Generic Drug Supply JV
• Pa. Court Won't Reopen Fixodent Nerve-Damage Suit
• Female Powerbrokers Q&A: Akin Gump's Kerry Berchem
• Female Powerbrokers Q&A: Locke Lord's Cynthia Bast
• J&J, Novartis Fined $22.4M Over Pay-For-Delay Deal
• Deals Rumor Mill: Novartis, Siemens, Blackstone
• Elliott Threatens To Block $8.4B Celesio Takeover
• Pharmacy Wholesalers Escape Drug-Inflation FCA Suit
• Heart Health Co. Sues Rival Over Genetic Test Patent
• Boehringer Fined $1M For Withholding Docs In MDL
• Merck Settles Fosamax Jaw-Injury Claims For $28M
• Enzo Contract Claims Trimmed In Affymetrix Med Testing Row
• Who Knew That Aredia, Zometa Caused De Jaw Vu?
• AstraZeneca Can't Shake Patent Suit Over Crestor Trials
• FDA Faults Biogen Over Sterility, 'Questionable' Paperwork
• Justices Won't Touch Smith & Nephew's $85M Patent Win
• Orchid, MPI Dodge Enzo Biochem's Patent, Contract Claims
• Female Powerbrokers Q&A: Gibson Dunn's Mary Murphy
• Female Powerbrokers Q&A: Arnold & Porter's Veronica Rendon
• High Court Passes On Lupron Labeling Suit
• Covidien Shells Out $860M For Israeli Medical Co.
• Post To Shell Out Nearly $700M For Healthy Brands
• High Court Denies Bid To Review Neurontin RICO Rulings
• How FRCP E-Discovery Amendments Could Affect You
• Deals Rumor Mill: Occidental, KKR, Freedom Group
• Hologic Hands Icahn 2 Board Seats To Head Off Proxy Fight
• NJ Appeals Court Will Hear Nostrum Attys' Fee Fight
• Medtronic Escapes Jury's $18M Surgical Fire Verdict
• Warner Chilcott Can't Dodge Interference Claim In IP Row
• 1st Circ. Ends Takeda FCA Suit But Limits Scope Of Ruling
• Former Cancer Research Exec Indicted Over $11M Grant
• FCA Report Author Backs Proposed Reforms Over Objections
• J&J Keeps Vaginal Mesh Suit Out Of Texas State Court
• Purdue, Impax Settle IP Claims In OxyContin Antitrust MDL
• Orion, Novartis Settle Patent Dispute Over Sedation Drug
• Roche Asks Fed. Circ. To Revive Boniva Dosage Patents
• US Asks Court To Junk Medical Device Co.'s Contract Suit
• Female Powerbrokers Q&A: Debevoise's Peggy Davenport
• Female Powerbrokers Q&A: Reed Smith's Dusty Kirk
• How Fed. Circ.'s Commil Ruling Could Affect Drug Patents
• FDA Dings Drugmakers Over Missing Pediatric Studies
• Feds Raid Reckitt Benckiser Pharmaceuticals Office In Va.
• Medical Product Co. Liable For ACA Tax, Judge Says
• Bristol-Myers Escapes Abilify Movement Disorder Suit
• BMS Urges Fed. Circ. To Revive Hepatitis B Drug Patent
• Amphastar Sanctioned For Veiling Docs Over Blood Thinner IP
• Female Powerbrokers Q&A: Chadbourne's Lori Hoberman
• Female Powerbrokers Q&A: O'Melveny's Carla Christofferson
• Merck Shells Out $2.6B For Specialty Chemicals Maker
• How Plaintiffs' Forum Shopping Paid Off In Novartis Case
• Consumer Protection Laws And Prescription Meds: A Poor Fit
• Ametek Drops $128M On Power Management Systems Maker
• Auxilium Loses Testim Patent Claims Against Upsher-Smith
• Bowman Opens San Diego Office With Drug, Device Attys
• FDA Reaches $1.25M Deal Over Mislabeled ASP Products
• 'Difficult To Compound' Drug List Gets Revived By FDA
• FDA Revises Equivalence Criteria For Generic Drug Approval
• Pamlab Can't Bar Virtus' Marketing In Unfair Competition Row
• FDA Warns Of Possible Philips Defibrillator Failure
• Merck Sued For Securities Fraud Over Cholesterol Drug Trial
• Getinge Plans $189M Offer For Pulsion Medical Systems
• Female Powerbrokers Q&A: Hunton & Williams' Lisa Sotto
• Female Powerbrokers Q&A: Hogan Lovells' Emily Yinger
• Abbott Settles NY False Ad Case Over Children's Drinks
• Deals Rumor Mill: GM, Essex Property, Men's Wearhouse
• Medicines Co. Puts Up $474M For Specialty Drugmaker
• Exela Tries To Escape Ruling, Nix Painkiller Patent Again
• FDA Tells Wockhardt To Assess Drug Facilities
• Multinational Pharmas: Expect Key Policy Shifts In China
• And Now A Word From The Panel: Too Hot Or Cold For An MDL?
• A Crash Course In Hot Product Liability Topics
• Belgian Court Rules Herbalife Not Pyramid Scheme, Co. Says
• AstraZeneca Deserves $76M In Drug Patent Suit, Judge Says
• Biopharma Co. Sues UC, Temple Over Proprietary Disclosure
• How They Won It: Irell Nixes Patent For Prenatal DNA Test
• Lundbeck Seizure Drug Poses Serious Skin Risks, FDA Warns
• Skanska Lands $95M In Lab Sale To REIT
• Female Powerbrokers Q&A: K&L Gates' Janice Hartman
• Female Powerbrokers Q&A: JAMS' Kimberly Taylor
• Elliott Wants Major Influence Over Buyout Target Celesio
• Gallant Pharma Pleads Guilty In Black-Market Drug Case
• J&J Unit Accused Of Losing Key Docs In Vaginal Mesh MDL
• FDA Again Blasts Pfizer Unit Over Quality-Control Mishaps
• Fed. Circ. Mulls Standing In Univ. Of Wis. Stem Cell IP Row
• Hunton Atty's Drunk Remark Not Insider Trading, Court Hears
• 4 Little-Noticed FCA Rulings Attys Need To Know
• Shire Fires Back At Mylan's Grab For Docs In Patent Row
• Generic-Reglan Suits Doomed By Catch-22, 6th Circ. Says
• HeartWare Buys CircuLite In Deal That Could Reach $350M
• J&J Asks Pa. Court To Keep Risperdal Docs Under Seal
• 23andMe Hit With False Ad Suit Over DNA Tests
• Diageo Shells Out $81M To Settle Aussie, NZ Thalidomide Suits
• Idenix Suits Target Gilead Hep C Drug Nearing Approval
• FDA Urges Providers To Work With Registered Compounders
• Following Up On Follow-On Biologics
• Pa. Appeals Court Upholds GSK Win In Paxil Pregnancy Suit
• Standing Issue Threatens 15 Zometa Suits In NJ
• Female Powerbrokers Q&A: DLA Piper's Tara Lee
• Female Powerbrokers Q&A: Jones Day's Lizanne Thomas
• Mild Modifications To The R&D Tax Credit